Nasdaq6d
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy (ATTR ...
Nasdaq7d
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use
BridgeBio Pharma BBIO recently received FDA approval for its pipeline candidate acoramidis for the treatment of adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related ...
Nasdaq10d
BridgeBio Pharma : FDA Approves Heart Disease Drug 'acoramidis'
(RTTNews) - BridgeBio Pharma Inc. (BBIO) announced that the U.S. Food and ... of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan ...
Nasdaq8d
BridgeBio FDA approval ‘significant clearing event,’ says Citi
Citi analyst David Lebowitz keeps a Buy rating on BridgeBio (BBIO) with a $45 price target after the FDA granted approval for Attruby for ATTR-CM. The drug’s label was in line with expectation ...
Nasdaq8d
BridgeBio price target raised to $49 from $43 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $49 from $43 and keeps a Buy rating on the shares. Acoramidis received regulatory approval with the label underscoring ...
HC Wainwright Boosts BridgeBio Pharma (NASDAQ:BBIO) Price Target to $49.00
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...
Nasdaq25d
Guru Fundamental Report for BBIO
Below is Validea's guru fundamental report for BRIDGEBIO PHARMA INC (BBIO). Of the 22 guru strategies we follow, BBIO rates highest using our Contrarian Investor model based on the published ...
Nasdaq10d
BridgeBio announces FDA approved Attruby for ATTR-CM patients
BridgeBio (BBIO) Pharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer of Transthyretin, or TTR, for the treatment of adults ...
Nasdaq5d
Biotech Alert: Searches spiking for these stocks today
Oncternal Therapeutics (ONCT), 910% surge in interest Scholar Rock (SRRK), 839% surge in interest Cabaletta Bio (CABA), 328% surge in interest Cassava Sciences (SAVA), 324% surge in interest ...
Nasdaq11d
BridgeBio Pharma call volume above normal and directionally bullish
Bullish option flow detected in BridgeBio (BBIO) Pharma with 2,983 calls trading, 1.0x expected, and implied vol increasing over 2 points to 132.22%. Dec-24 30 calls and Dec-24 35 calls are the ...
BridgeBio Pharma (NASDAQ:BBIO) Given New $45.00 Price Target at Bank of America
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
manilatimes2h
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology
This milestone signifies a significant milestone in the collaboration between the two companies, and reinforces the potential ...